Biotech | September 10, 2025
Evonik and Ethris partner to expand offerings for nucleic acid delivery
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Increases speed to market for drug developers working on nucleic acid therapeutics
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Subscribe To Our Newsletter & Stay Updated
